{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:01:05Z","timestamp":1780920065394,"version":"3.54.1"},"reference-count":210,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/19420862.2026.2680773","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:09:39Z","timestamp":1780916979000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous drug delivery of high concentration antibody products \u2013 part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentations"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7720-4780","authenticated-orcid":false,"given":"Indrajit","family":"Ghosh","sequence":"first","affiliation":[{"name":"Bristol Myers Squibb","place":["New Brunswick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyash","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["New Brunswick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiten","family":"Gutka","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["New Brunswick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srini","family":"Sridharan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["New Brunswick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilbir","family":"Bindra","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["New Brunswick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2205540"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2580696"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbab027"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.03.017"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2211185"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27165094"},{"key":"e_1_3_4_8_1","doi-asserted-by":"crossref","unstructured":"Li J Krause M Tu R. Protein instability at interfaces during drug product development fundamental understanding evaluation and mitigation: fundamental understanding evaluation and mitigation. 2021.","DOI":"10.1007\/978-3-030-57177-1"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12247-025-10323-x"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.12.022"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0368"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00361-3"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2026.115793"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2169440"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44174-025-00479-y"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2402713"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44395-025-00012-6"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-024-00968-w"},{"key":"e_1_3_4_19_1","article-title":"Transitioning from vial to subcutaneous injection devices for biological drug products","author":"Adler Adler","year":"2024","unstructured":"Adler Adler, Allmendinger A, Mahler H. Transitioning from vial to subcutaneous injection devices for biological drug products. ONdrugDelivery. 2024;https:\/\/www.ondrugdelivery.com\/transitioning-from-vial-to-subcutaneous-injection-devices-for-biological-drug-products\/.","journal-title":"ONdrugDelivery"},{"key":"e_1_3_4_20_1","unstructured":"Sanofi. Asco: New Sarclisa data support subcutaneous administration with on-body injector. 2025. https:\/\/www.sanofi.com\/en\/media-room\/news\/asco-new-sarclisa-data-support-subcutaneous-administration."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00626-1"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-024-03683-5"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S287323"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114156"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103914"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2024.1377443"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2023.2219891"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114474"},{"key":"e_1_3_4_29_1","unstructured":"(FDA) USFaDA. Summary basis for regulatory action: hyaluronidase human recombinant for further manufacturing use (BLA 761313). Report no.: BLA 761313. Silver Spring (MD) USA: Administration USFaD; 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/summary_review\/2024\/761313Orig1s000SumR.pdf."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbae028"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103877"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113675"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040397"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-025-03154-z"},{"key":"e_1_3_4_35_1","first-page":"12","volume-title":"On\u2011Body delivery systems \u2013 news and trends","author":"Oakley T","year":"2022","unstructured":"Oakley T. On\u2011body delivery systems \u2013 news and trends. In: On\u2011Body delivery systems \u2013 news and trends. ONdrugDelivery; 2022. p. 12\u201316."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.008"},{"key":"e_1_3_4_37_1","unstructured":"Whiskin C. New autoinjector for risankizumab (Skyrizi) [Blog] Charlton Health Pharmacy Blog (The Charlton Centre). [accessed 2026 May]. https:\/\/charltonhealthcare.com\/new-autoinjector-for-risankizumab-skyrizi\/."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-0433-8"},{"key":"e_1_3_4_39_1","unstructured":"U.S. Food and Drug Administration. Bridging for drug\u2011device and biologic\u2011device combination products: draft guidance for industry. Report no.: FDA-2019-D-5585. Silver Spring (MD): U.S. Food and Drug Administration; 2019 [accessed 2026 May]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bridging-drug-device-and-biologic-device-combination-products."},{"key":"e_1_3_4_40_1","volume-title":"Humira\u00ae (adalimumab) injection, for subcutaneous use (highlights of prescribing information)","year":"2021","unstructured":"Humira\u00ae (adalimumab) injection, for subcutaneous use (highlights of prescribing information). AbbVie Inc.; 2021."},{"key":"e_1_3_4_41_1","volume-title":"Skyrizi\u00ae (risankizumab-rzaa) injection, for subcutaneous or intravenous use (highlights of prescribing information)","year":"2022","unstructured":"Skyrizi\u00ae (risankizumab-rzaa) injection, for subcutaneous or intravenous use (highlights of prescribing information). AbbVie Inc.; 2022 [accessed 2026 May]."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2024.1486318"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2285277"},{"key":"e_1_3_4_44_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-3-319-90603-4_9","volume-title":"Challenges in protein product development","author":"Dimitrova MN","year":"2018","unstructured":"Dimitrova MN, Bee JS, Lu L, Fernandez JE. Development of prefilled syringe combination products for biologics. In: Warne NW Mahler H-C. editors. Challenges in protein product development. Cham: Springer International Publishing; 2018. p. 203\u2013224."},{"key":"e_1_3_4_45_1","unstructured":"International Organization for Standardization. Prefilled syringe; part 8: requirements and test methods for finished prefilled syringes. Geneva Switzerland: International Organization for Standardization; 2016 [accessed 2026 May]. https:\/\/www.iso.org\/standard\/66036.html."},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02671-2"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S170636"},{"key":"e_1_3_4_48_1","unstructured":"Ascendis Pharma Endocrinology Inc. Instructions for use (Skytrofa auto injector for Skytrofa cartridges: single patient use. 2021 [accessed 2026 May]. https:\/\/skytrofa.com\/pdf\/Skytrofa_Instructions_For_Use.pdf."},{"key":"e_1_3_4_49_1","unstructured":"Ascendis Pharma Endocrinology Inc. The Skytrofa\u00ae auto\u2011injector. SKYTROFA\u00ae (lonapegsomatropin\u2011tcgd) Official Website; 2024. https:\/\/skytrofa.com\/discover\/auto-injector\/."},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1073"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.S389865"},{"key":"e_1_3_4_52_1","unstructured":"Regeneron Pharmaceuticals I and sanofi-aventis U.S. Llc DUPIXENT\u00ae(dupilumab) injection for subcutaneous use (highlights of prescribing information). 2025 [accessed 2026 May]. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf."},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1373"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-011-9617-y"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.3109\/10837450.2014.982825"},{"key":"e_1_3_4_56_1","first-page":"8","article-title":"Subcutaneous drug delivery: adapting to high\u2011viscosity, large\u2011volume demands","author":"Fontanellaz R","year":"2024","unstructured":"Fontanellaz R, Schneider A. Subcutaneous drug delivery: adapting to high\u2011viscosity, large\u2011volume demands. ONdrugDelivery. 2024; 8\u201312.","journal-title":"ONdrugDelivery"},{"key":"e_1_3_4_57_1","first-page":"24","article-title":"Innovations in prefilled biologics","volume":"48","author":"Forcinio H","year":"2024","unstructured":"Forcinio H. Innovations in prefilled biologics. Pharm Technol. 2024;48:24\u201327. https:\/\/www.pharmtech.com\/view\/innovations-in-prefilled-biologics.","journal-title":"Pharm Technol"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01101-6"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2016-000266"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00245-0"},{"key":"e_1_3_4_61_1","unstructured":"AbbVie Inc. Humira\u00ae (adalimumab) citrate\u2011free injection: patient information sheet. 2018 [accessed 2026 May]."},{"key":"e_1_3_4_62_1","unstructured":"Novartis Europharm Ltd. Xolair\u00ae (omalizumab) 150 mg and 300 mg solution for injection in pre\u2011filled syringe. Package leaflet: information for the patient. (eMC) EMC. [accessed 2026 May]. https:\/\/www.medicines.org.uk\/emc\/files\/pil.4725.pdf."},{"key":"e_1_3_4_63_1","unstructured":"UCB Inc. CIMZIA (certolizumab pegol) for injection for subcutaneous use (highlights of prescribing information). 2025 [accessed 2026 May]. https:\/\/www.ucb-usa.com\/cimzia-prescribing-information.pdf."},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2022.2116425"},{"key":"e_1_3_4_65_1","unstructured":"Ypsomed delivery systems YpsoMate\u00ae 2.25\/Pro \u2013 2.25 mL two-step autoinjector for biologics. 2024 [accessed 2026 May]. https:\/\/www.ypsomed.com\/en\/products\/autoinjectors\/ypsomate-2-25."},{"key":"e_1_3_4_66_1","unstructured":"Teva Pharmaceuticals USA I. AJOVY\u00ae (fremanezumab-vfrm) injection for subcutaneous use (highlights of prescribing information). 2025 [accessed 2026 May]. https:\/\/www.ajovy.com\/globalassets\/ajovy\/ajovy-pi.pdf."},{"key":"e_1_3_4_67_1","first-page":"8","article-title":"Subcutaneous drug delivery: adapting to high-viscosity, large-volume demands","author":"Fontanellaz R","year":"2024","unstructured":"Fontanellaz R, Schneider A. Subcutaneous drug delivery: adapting to high-viscosity, large-volume demands. ONdrugDelivery. 2024; 8\u201312.","journal-title":"ONdrugDelivery"},{"key":"e_1_3_4_68_1","unstructured":"BD Pharmaceutical Systems. BD Neopak\u2122 glass prefillable syringe platform \u2013 features and benefits. 2024. https:\/\/www.bd.com\/en-us\/products-and-solutions\/products\/product-families\/neopak-glass-pre-fillable-syringe-platform."},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2021.2018069"},{"key":"e_1_3_4_70_1","unstructured":"Neumeier M. Advancing lyophilised drug development in dual-chamber systems. 2025. https:\/\/www.ondrugdelivery.com\/advancing-lyophilised-drug-development-in-dual-chamber-systems\/."},{"key":"e_1_3_4_71_1","unstructured":"SCHOTT Pharma. Cartridges double chamber (DC). 2024 [accessed 2026 May]. https:\/\/www.schott-pharma.com\/en\/products\/pharmaceutical-cartridges\/cartridges-double-chamber."},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01509-4"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.05.029"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0b013e31824d2271"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00726-7"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-024-00608-0"},{"key":"e_1_3_4_77_1","volume-title":"Enhaze drug delivery technology: advancing subcutaneous drug delivery using recombinant human hyaluronidase PH20","author":"Tannenbaum R","year":"2022","unstructured":"Tannenbaum R, Kang DW. Enhaze drug delivery technology: advancing subcutaneous drug delivery using recombinant human hyaluronidase PH20. In: Enhaze drug delivery technology: advancing subcutaneous drug delivery using recombinant human hyaluronidase PH20. Basel: Karger Publishers; 2022."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2018.1551442"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1981286"},{"key":"e_1_3_4_80_1","unstructured":"Halozyme I. Enhaze\u00ae drug delivery technology Halozyme. 2026. https:\/\/halozyme.com\/drug-delivery-technologies\/enhanze\/."},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-025-01883-z"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.06.021"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104441"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2484278"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf9166"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.7.527"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/dss.0000000000001279"},{"key":"e_1_3_4_88_1","unstructured":"AbbVie Inc. Instructions for use SKYRIZI\u00ae on-body injector risankizumab-rzaa injection for subcutaneous use. https:\/\/www.humirapro.com\/content\/dam\/rxabbvie\/pdf\/skyrizi_ifu_obi.pdf."},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.2.1.3"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126442"},{"key":"e_1_3_4_91_1","unstructured":"Apellis Pharmaceuticals I. Empaveli\u00ae (pegcetacoplan) injection for subcutaneous use (highlights of prescribing information). 2023 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215014s003lbl.pdf."},{"key":"e_1_3_4_92_1","unstructured":"Novartis Pharmaceuticals Corporation. Cosentyx\u00ae (secukinumab) injection for subcutaneous or intravenous use (highlights of prescribing information). 2023 [accessed 2026 May]. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/cosentyx.pdf."},{"key":"e_1_3_4_93_1","unstructured":"Genentech USA I. Xolair\u00ae (omalizumab) injection for subcutaneous use (highlights of prescribing information). 2024 [accessed 2026 May]. https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf."},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.05.027"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.4.427"},{"key":"e_1_3_4_96_1","unstructured":"Argenx US. Vyvgart Hytrulo\u00ae (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use (highlights of prescribing information). 2025 [accessed 2026 May]. https:\/\/argenx.com\/content\/dam\/argenx-corp\/products\/vyvgart-hytrulo-prescribing-information.pdf."},{"key":"e_1_3_4_97_1","unstructured":"Takeda Pharmaceuticals U.S.A. I. HyQvia\u00ae [immune globulin infusion (human) 10% with recombinant human hyaluronidase] solution: dosing & administration guide. 2025 [accessed 2026 May]. https:\/\/www.hyqviahcp.com\/content\/dam\/takeda\/imported\/hyqvia\/pdfs\/dosing-and-administration.pdf."},{"key":"e_1_3_4_98_1","unstructured":"Genentech I. Rituxan Hycela\u2122 (rituximab and hyaluronidase human) injection for subcutaneous use. 2017 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761064s000lbl.pdf."},{"key":"e_1_3_4_99_1","unstructured":"Genentech USA I. Rituxan Hycela\u00ae (rituximab and hyaluronidase human) injection for subcutaneous use (highlights of prescribing information). 2021 [accessed 2026 May]. https:\/\/www.gene.com\/download\/pdf\/rituxan_hycela_prescribing.pdf."},{"key":"e_1_3_4_100_1","unstructured":"Genentech I. Phesgo\u00ae (pertuzumab trastuzumab and hyaluronidase-zzxf) injection for subcutaneous use (highlights of prescribing information). 2024 [accessed 2026 May]. https:\/\/www.gene.com\/download\/pdf\/phesgo_prescribing.pdf."},{"key":"e_1_3_4_101_1","unstructured":"Janssen Biotech I. Darzalex Faspro\u00ae (daratumumab and hyaluronidase-fihj) injection for subcutaneous use (highlights of prescribng information). 2021 [accessed 2026 May]. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX+Faspro-pi.pdf."},{"key":"e_1_3_4_102_1","unstructured":"Inc; A. FDA approves first and only single monthly injection for a PCSK9 inhibitor. 2016 [accessed 2026 May]. https:\/\/www.amgen.com\/newsroom\/press-releases\/2016\/07\/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor."},{"key":"e_1_3_4_103_1","unstructured":"Amgen Inc. Repatha (evolocumab) injection for subcutaneous use (highlights of prescribing information). 2020 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125522s29s31lbl.pdf."},{"key":"e_1_3_4_104_1","unstructured":"Alexion Pharmaceuticals I. Ultomiris\u00ae (ravulizumab-cwvz) injection for intravenous use (medication guide). 2025 [accessed 2026 May]. https:\/\/ultomiris.com\/pdf\/ultomiris-med-guide.pdf."},{"key":"e_1_3_4_105_1","unstructured":"Baxalta US Inc. Cuvitru immune globulin subcutaneous (human) 20% solution (highlights of prescribing information). 2021 [accessed 2026 May]. https:\/\/www.fda.gov\/media\/100531\/download."},{"key":"e_1_3_4_106_1","unstructured":"Pfizer Inc. Cutaquig\u00ae (immune globulin subcutaneous (human) - hipp) 16.5% solution (highlights of prescribing information). 2021 [accessed 2026 May]. https:\/\/www.fda.gov\/media\/119234\/download?attachment."},{"key":"e_1_3_4_107_1","unstructured":"Grifols Therapeutics LLC. Xembify (immune globulin subcutaneous human \u2013 klhw) 20% solution (highlights of prescribing information). 2019 [accessed 2026 May]. https:\/\/www.fda.gov\/media\/128601\/download."},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.2147\/mder.S545256"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00425-w"},{"key":"e_1_3_4_110_1","doi-asserted-by":"crossref","unstructured":"McCarthy R. Human factors engineering and user-centered design principles in the design and development of device combination products for special patients populations. 2025.","DOI":"10.54941\/ahfe1006189"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1954906"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2024.2356678"},{"key":"e_1_3_4_113_1","unstructured":"U.S. Food and Drug Administration. Applying human factors and usability engineering to medical devices: guidance for industry and food and drug administration staff. 2016 [accessed 2026 May]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/applying-human-factors-and-usability-engineering-medical-devices."},{"key":"e_1_3_4_114_1","unstructured":"U.S. Food and Drug Administration. Application of human factors engineering principles for combination products: questions and answers: guidance for industry and FDA staff. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/application-human-factors-engineering-principles-combination-products-questions-and-answers."},{"key":"e_1_3_4_115_1","unstructured":"U.S. Food and Drug Administration. Purpose and content of use-related risk analyses for drugs biological products and combination products. 2024 [accessed 2026 May]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/purpose-and-content-use-related-risk-analyses-drugs-biological-products-and-combination-products."},{"key":"e_1_3_4_116_1","unstructured":"Amgen Inc. How the Neulasta\u00ae Onpro\u00ae on-body injector works. 2025 [accessed 2026 May]. https:\/\/www.neulasta.com\/stay-at-home-with-neulasta-onpro."},{"key":"e_1_3_4_117_1","unstructured":"Amgen Inc. Neulasta\u00ae (pegfilgrastim) injection for subcutaneous use (highlights of prescribing information). 2019 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125031s198lbl.pdf."},{"key":"e_1_3_4_118_1","unstructured":"Amgen Inc. Physician package insert Neulasta\u2122 (pegfilgrastim). 2002 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/125031_000_Neulasta_prntlbl.pdf."},{"key":"e_1_3_4_119_1","unstructured":"Coherus BioSciences I. Patient instructions for use: UDENYCA ONBODYTM (pegfilgrastim-cbqv) injection for subcutaneous use (dose delivery information). [accessed 2026 May]. https:\/\/www.udenyca.com\/pdf\/udenyca-instructions-for-use_obi-patient.pdf."},{"key":"e_1_3_4_120_1","unstructured":"Coherus BioSciences I. Udenyca\u00ae (pegfilgrastim-cbqv) injection for subcutaneous use (highlights of prescribing information). 2023 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761039Orig1s015lbl.pdf."},{"key":"e_1_3_4_121_1","unstructured":"Amgen Inc. Repatha\u00ae Pushtronex\u00ae system (on-body-infusor with prefilled cartridge) discontinuation. 2024 [accessed 2026 May]. https:\/\/www.repatha.com\/~\/media\/12A733ED009842C68F1DA5F83532C636.ashx."},{"key":"e_1_3_4_122_1","unstructured":"Yeh H-JL-R Cheng T-C. Novel solutions for ultra-large-volume wearable and portable subcutaneous injectors. 2025. https:\/\/ondrugdelivery.com\/novel-solutions-for-ultra-large-volume-wearable-and-portable-subcutaneous-injectors\/."},{"key":"e_1_3_4_123_1","article-title":"Continuous subcutaneous apomorphine infusion for treatment of Parkinson disease","author":"Fernando L","year":"2025","unstructured":"Fernando L, Pag\u00e1n M, Jason Aldred FAAN, Maria Cristina Ospina MD. Continuous subcutaneous apomorphine infusion for treatment of Parkinson disease. NeurologyLive. 2025.","journal-title":"NeurologyLive"},{"key":"e_1_3_4_124_1","unstructured":"EVER Pharma GmbH. Dacepton 5 mg\/ml solution for infusion; abbreviated prescribing information. 2025 [accessed 2026 May]. https:\/\/www.d-minecare.com\/wp-content\/uploads\/2022\/07\/D-mine_PumpSalesAid_INT_V02.pdf."},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13810"},{"key":"e_1_3_4_126_1","unstructured":"Enable injections: High-volume wearable drug delivery systems injections e; 2025. [accessed 2026 May]. https:\/\/enableinjections.com\/."},{"key":"e_1_3_4_127_1","unstructured":"Enable Injections Inc. Enable injections enters strategic partnership with Sanofi. 2019 [accessed 2026 May]. https:\/\/drug-dev.com\/enable-injections-enters-strategic-partnership-with-sanofi\/."},{"key":"e_1_3_4_128_1","unstructured":"Keenan J. Enable injections Incyte Ink drug delivery collab focused on chronic blood bone marrow conditions. 2025. https:\/\/www.fiercebiotech.com\/medtech\/fda-slams-exthera-warning-letter-over-controversial-blood-filter-device."},{"key":"e_1_3_4_129_1","volume-title":"Enhancing the patient and nurse experience in large volume subcutaneous drug delivery","author":"Omar Rahman BF","year":"2024","unstructured":"Omar Rahman BF, Gorski L. Enhancing the patient and nurse experience in large volume subcutaneous drug delivery. Ltd FP; 2024."},{"key":"e_1_3_4_130_1","unstructured":"Ypsomed AG. Ypsodose: the clinical ready 10mL patch injector. Burgdorf Switzerland; 2023 [accessed 2026 May]. https:\/\/www.ypsomed.com\/en\/news-insights\/product-news\/product-news-detail-page\/ypsodose-the-clinical-ready-10ml-patch-injector."},{"key":"e_1_3_4_131_1","unstructured":"Nemera Inc. Symbioze\u00ae: smart and sustainable on-body injector platform to improve patients\u2019 injection experience. Lyon France; 2025 [accessed 2026 May]. https:\/\/www.nemera.net\/products\/parenteral\/wearables-symbioze\/."},{"key":"e_1_3_4_132_1","unstructured":"Neulasta\u00ae Onpro\u00aeinformation page. Amgen Inc."},{"key":"e_1_3_4_133_1","unstructured":"Accord BioPharma I. Udenyca autoinjector instructions for use. 2025 [accessed 2026 May]. https:\/\/udenyca.com\/pdf\/udenyca-instructions-for-use_ai.pdf."},{"key":"e_1_3_4_134_1","unstructured":"Merck Sharp & Dohme LLC. Keytruda QLEX\u2122 (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use (highlights of prescribing information). 2025 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761467s000lblOrig1.pdf#page=177."},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2252999"},{"key":"e_1_3_4_136_1","unstructured":"Genentech I. Herceptin Hylecta\u2122 (trastuzumab and hyaluronidase-oysk) injection for subcutaneous use (highlights of prescribing information). 2019 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761106s000lbl.pdf."},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279459"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155221999712"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2550757"},{"key":"e_1_3_4_140_1","unstructured":"Janssen Biotech I. Simponi\u00ae (golimumab) injection for subcutaneous use (highlights of prescribing information). 2025 [accessed 2026 May]. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/SIMPONI-pi.pdf."},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i5.275"},{"key":"e_1_3_4_142_1","unstructured":"Bristol-Myers Squibb Company. Orencia\u00ae (abatacept) injection for subcutaneous or intravenous use. 2024 [accessed 2026 May]. https:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf."},{"key":"e_1_3_4_143_1","unstructured":"Regeneron Pharmaceuticals IaS-aUSL. Praluent\u00ae (alirocumab) injection for subcutaneous use (highlights of prescribing information). 2017 [accessed 2026 May]. https:\/\/products.sanofi.us\/praluent\/praluent.pdf."},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00937"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20079"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2015.07.002"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2025.114940"},{"key":"e_1_3_4_148_1","volume-title":"Xolair\u00ae (omalizumab) injection, for subcutaneous use (highlights of prescribing information)","unstructured":"Xolair\u00ae (omalizumab) injection, for subcutaneous use (highlights of prescribing information). Genentech USA, Inc."},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00453"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.12.029"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119523"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1039\/d1cb00067e"},{"key":"e_1_3_4_153_1","volume-title":"Benlysta (belimumab) injection, for subcutaneous and intravenous use (highlights of prescribing information)","year":"2025","unstructured":"Benlysta (belimumab) injection, for subcutaneous and intravenous use (highlights of prescribing information). GlaxoSmithKline LLC; 2025."},{"key":"e_1_3_4_154_1","unstructured":"Genentech Inc. Enspryng\u00ae (satralizumab-mwge) injection for subcutaneous use (highlights of prescribing information). 2022 [accessed 2026 May]. https:\/\/www.gene.com\/download\/pdf\/enspryng_prescribing.pdf."},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbad022"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2398-1"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1128606"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21232"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.1682"},{"key":"e_1_3_4_160_1","unstructured":"AbbVie Inc. Humira injection patient tear sheet. North Chicago (IL); 2018 [accessed 2026 May]. https:\/\/www.humira.com\/content\/dam\/humira\/documents\/pdf\/Humira-citrate-free-information-sheet.pdf."},{"key":"e_1_3_4_161_1","unstructured":"GlaxoSmithKline LLC. Nucala (mepolizumab) injection for subcutaneous use (highlights of prescribing information). 2023 [accessed 2026 May]. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF."},{"key":"e_1_3_4_162_1","unstructured":"Bausch Health US L. Siliq\u00ae (brodalumab) injection for subcutaneous use (highlights of prescribing information). 2024 [accessed 2026 May]. https:\/\/pi.bauschhealth.com\/globalassets\/BHC\/PI\/Siliq-pi.pdf."},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0385-x"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-012-9878-0"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121706"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02919-4"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22141"},{"key":"e_1_3_4_168_1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9050441"},{"key":"e_1_3_4_169_1","unstructured":"Merck & Co. Inc. Zinplava\u2122 (bezlotoxumab) injection for intravenous use (highlights of prescribing information). 2016 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761046s000lbl.pdf."},{"key":"e_1_3_4_170_1","unstructured":"Company. B-MS. Yervoy (ipilimumab) injection for intravenous use (highlights of prescribing information). [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125377s110lbl.pdf."},{"key":"e_1_3_4_171_1","unstructured":"Spectrum Pharmaceuticals Inc. Zevalin\u00ae (ibritumomab tiuxetan) injection for intravenous use (highlights of prescribing information). 2018 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125019s227lbl.pdf."},{"key":"e_1_3_4_172_1","unstructured":"AstraZeneca Inc. Beyfortus (nirsevimab-alip) injection for intramuscular use (highlights of prescribing information). 2023 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761328s000lbl.pdf."},{"key":"e_1_3_4_173_1","unstructured":"Eli Lilly and Company. Ebglyss (lebrikizumab-lbkz) injection for subcutaneous use (highlights of prescribing information). 2025 [accessed 2026 May]. https:\/\/pi.lilly.com\/us\/ebglyss-uspi.pdf."},{"key":"e_1_3_4_174_1","first-page":"469","article-title":"Stability, formulation, and delivery of biopharmaceuticals. In; protein therapeutics","author":"Mahler H-C","year":"2017","unstructured":"Mahler H-C, Allmendinger A. Stability, formulation, and delivery of biopharmaceuticals. In; protein therapeutics. Stab Formulat Del Biopharmaceut. 2017; 469\u2013491.","journal-title":"Stab Formulat Del Biopharmaceut"},{"key":"e_1_3_4_175_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-025-01856-2"},{"key":"e_1_3_4_176_1","unstructured":"Genentech I. Xolair\u00ae dosing and administration \u2013 autoinjector information. 2025. https:\/\/www.xolairhcp.com\/allergic-asthma\/dosing-and-administration\/administration.html."},{"key":"e_1_3_4_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.01.011"},{"key":"e_1_3_4_178_1","unstructured":"GlaxoSmithKline LLC. Benlysta (belimumab) for injection (highlights of prescribing information). 2025 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761043s034lbl.pdf."},{"key":"e_1_3_4_179_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.10937"},{"key":"e_1_3_4_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.07.039"},{"key":"e_1_3_4_181_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2113053"},{"key":"e_1_3_4_182_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6162"},{"key":"e_1_3_4_183_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0295-0"},{"key":"e_1_3_4_184_1","doi-asserted-by":"publisher","DOI":"10.1081\/bip-120024210"},{"key":"e_1_3_4_185_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243790"},{"key":"e_1_3_4_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.02.014"},{"key":"e_1_3_4_187_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115624"},{"key":"e_1_3_4_188_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3150"},{"key":"e_1_3_4_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.05.009"},{"key":"e_1_3_4_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.08.019"},{"key":"e_1_3_4_191_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1902925"},{"key":"e_1_3_4_192_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.11.014"},{"key":"e_1_3_4_193_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2019.1663428"},{"key":"e_1_3_4_194_1","doi-asserted-by":"publisher","DOI":"10.5414\/cp203023"},{"key":"e_1_3_4_195_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00789-9"},{"key":"e_1_3_4_196_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00912-5"},{"key":"e_1_3_4_197_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.04.015"},{"key":"e_1_3_4_198_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2385"},{"key":"e_1_3_4_199_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.11.015"},{"key":"e_1_3_4_200_1","unstructured":"U.S. Food and Drug Administration. Human factors studies and related clinical study considerations in combination product design and development: draft guidance for industry and FDA staff. 2016 [accessed 2026 May]. https:\/\/www.fda.gov\/files\/about%20fda\/published\/Human-Factors-Studies-and-Related-Clinical-Study-Considerations-in-Combination-Product-Design-and-Development.pdf."},{"key":"e_1_3_4_201_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080359"},{"key":"e_1_3_4_202_1","article-title":"FDA approves first and only single monthly injection for a PCSK9 inhibitor","author":"Inc","year":"2016","unstructured":"Inc. FDA approves first and only single monthly injection for a PCSK9 inhibitor. FDA Approves First Only Single Mon Injection A PCSK9 Inhibitor. 2016.","journal-title":"FDA Approves First Only Single Mon Injection A PCSK9 Inhibitor"},{"key":"e_1_3_4_203_1","unstructured":"Amgen Inc. Approval package for Repatha (application number: 125522Orig1s045). 2025 [accessed 2026 May]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/125522Orig1s045.pdf."},{"key":"e_1_3_4_204_1","unstructured":"Approval Package for Repatha injection (evolocumab)."},{"key":"e_1_3_4_205_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0620-7"},{"key":"e_1_3_4_206_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02339-3"},{"key":"e_1_3_4_207_1","unstructured":"Tracy D. Phase III trial shows Leqembi subcutaneous autoinjector demonstrates comparable efficacy safety to IV for early Alzheimer maintenance. Applied Clinical Trials. https:\/\/www.appliedclinicaltrialsonline.com\/view\/phase-iii-trial-leqembi-subcutaneous-autoinjector-comparable-efficacy-safety-iv-early-alzheimer-maintenance."},{"key":"e_1_3_4_208_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_4_209_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082852"},{"key":"e_1_3_4_210_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz70859_104691"},{"key":"e_1_3_4_211_1","unstructured":"Subcutaneous lecanemab: expanding options for maintenance therapy in early Alzheimer\u2019s disease. https:\/\/mindthegulf.com\/article.php?id=136."}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2026.2680773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:10:27Z","timestamp":1780917027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2026.2680773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":210,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/19420862.2026.2680773"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2026.2680773","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2680773"}}